Clinical Trial Update: Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Muvalaplin for reducing major cardiovascular events in adults with elevated lipoprotein(a) and ASCVD. The trial is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Muvalaplin

Snippet

Sponsor: Eli Lilly and Company | Conditions: Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Status: RECRUITING